Phaseline

Companies › In8bio

In8bio: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Allogeneic genetically modified gamma-delta T cells
Gene-modified gamma-delta T cell therapy
–Phase 1GlioblastomaDec 2026
Autologous genetically modified gamma-delta T cells
Gene-modified gamma-delta T cell therapy
–Phase 1GlioblastomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05664243Autologous genetically modified gamma-delta T cellsPhase 1GlioblastomaOncologyDec 2026
NCT05664243Allogeneic genetically modified gamma-delta T cellsPhase 1GlioblastomaOncologyDec 2026

From the company's SEC filings

Cash of $14m on 2026-09-30; operating cash outflow about $17m a year; runway about 10 months at that burn, to Jul 2027

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.